Ignite Creation Date:
2024-05-06 @ 12:13 AM
Last Modification Date:
2024-10-26 @ 10:46 AM
Study NCT ID:
NCT01516580
Status:
UNKNOWN
Last Update Posted:
2017-06-14
First Post:
2012-01-19
Brief Title:
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia Rituximab Evaluation in High Risk Patients
Sponsor:
Gustave Roussy Cancer Campus Grand Paris
Organization:
Gustave Roussy Cancer Campus Grand Paris
Study Overview
Official Title:
Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial
Status:
UNKNOWN
Status Verified Date:
2017-06
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the trial is to test whether adding 6 injections of rituximab to standard Lymphome malin B LMB chemotherapy regimen improves the Event Free Survival EFS compared with LMB chemotherapy alone in children adolescents with advanced stage B-cell Non-Hodgkin Lymphoma NHL B-Acute Leukemia B-ALstage III and LDH Nx2 any stage IV or B-AL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2010-019224-31 | EUDRACT_NUMBER | None | None |